| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Cardiovascular Division, Henry Ford Heart and Vascular Institute, Detroit, MI, USA
2 Procter and Gamble, Cincinati, OH, USA
* To whom correspondence should be addressed. E-mail: hsabbah1{at}hfhs.org.
Background - Matrix metalloproteinases (MMPs) contribute to the progression of left ventricular (LV) dysfunction and remodeling associated with heart failure (HF). The present study examined the long-term effects of a selective MMP inhibitor, PG-530742 (PG), on the progression of LV dysfunction and remodeling in dogs with HF. Methods and Results - Chronic HF (LV ejection fraction [LVEF] 
36%) was produced by multiple sequential intracoronary microembolizations in 24 dogs. Two weeks after the last embolization, dogs were randomized to 3 months of therapy with either high-dose PG (3.5mg/kg, n=8) (HD), low-dose PG (0.2mg/kg, n=8) (LD), or to a matched placebo (PL, n=8). PG has been shown to produce complete inhibition of MMPs 2, 3, 9, and -13, while sparing MMPs-1 and -7. Hemodynamic and echocardiographic measurements were made before and 3 months after initiating therapy. In PL dogs and in LD dogs, LVEF decreased significantly, and LV end-systolic volume (ESV) and LV end-diastolic volume (EDV) increased significantly during the 3-month follow-up period. Whereas, in HD dogs, EF increased from 36±1 % to 40±1 % (p=0.003), EDV and ESV decreased (59±4 vs. 57±4 ml, p=0.02, 38±2 vs. 34±2 ml, p=0.00001). Compared to controls, treatment with HD showed 30% reduction in replacement fibrosis, 29% reduction in interstitial fibrosis and 28% reduction in myocyte cross-sectional area. mRNA expression of selective MMPs was also reduced in LV tissue in HD-treated dogs but not LD-treated dogs.Conclusions - In dogs with moderate heart failure, long-term monotherapy with high dose selective MMP inhibitor, PG-53072, prevents LV remodeling and the progression of global LV dysfunction.
This article has been cited by other articles:
|
|
 |
|
  J. A. Dixon and F. G. Spinale Large Animal Models of Heart Failure: A Critical Link in the Translation of Basic Science to Clinical Practice Circ Heart Fail, May 1, 2009; 2(3): 262 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rastogi, V. G. Sharov, S. Mishra, R. C. Gupta, B. Blackburn, L. Belardinelli, W. C. Stanley, and H. N. Sabbah Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2149 - H2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Rietzschel, M. Langlois, M. L. De Buyzere, P. Segers, D. De Bacquer, S. Bekaert, L. Cooman, P. Van Oostveldt, P. Verdonck, G. G. De Backer, et al. Oxidized Low-Density Lipoprotein Cholesterol Is Associated With Decreases in Cardiac Function Independent of Vascular Alterations Hypertension, September 1, 2008; 52(3): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
